glp 1 optimal Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society it mixes well What should you actually expect
Description
doi: 10.1111/exd.12081 187 HoganAETobinAMAhernTCorriganMAGaoatsweGJacksonRet al
Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
Common side effects include: Gastrointestinal issues: Nausea (15-20%), vomiting (5-9%), diarrhea (8%), stomach pain (6-7%), and constipation (3-7%) Mild discomfort: Headache, dizziness, fatigue, bloating, gas, or heartburn Appetite changes: Some individuals report loss of appetite Most side effects are temporary and improve over time
After the initial four weeks, the dosage is increased to 1 mg once weekly
